Researchers at Queen Mary University of London’s School of Biological and Behavioural Sciences have identified that the TOR inhibitor rapalink-1, currently in development for cancer treatment, significantly prolongs chronological lifespan in fission yeast. This discovery, led by Charalampos Rallis, PhD, highlights previously unknown TOR-regulated genes that may influence aging, suggesting that both pharmaceutical and natural metabolites could modulate lifespan through the TOR pathway.
The TOR pathway is crucial for growth and aging, with implications for age-related diseases such as cancer and neurodegeneration. The findings indicate that rapalink-1 not only inhibits TORC1, the growth-promoting arm of the pathway, but also reveals a metabolic feedback loop involving agmatinases, enzymes that convert agmatine into polyamines. This relationship underscores a balance between short-term cell growth and long-term survival, suggesting that the modulation of TOR activity through dietary or microbial interventions could offer new strategies for promoting healthy aging.
As the research progresses, the implications for the pharmaceutical industry are significant. The study opens avenues for combining TOR-targeting drugs with dietary strategies to enhance longevity and combat metabolic diseases. Rallis emphasizes the need for cautious interpretation of agmatine supplementation, as its effects are context-dependent and may not always yield beneficial outcomes. This research not only advances our understanding of aging mechanisms but also points to potential therapeutic targets for improving healthspan.
Open the full market picture for your next decision →
